Genvolt at PharmSci 2026 | Electrospinning | Electrospraying | Electrohydrodynamic Atomisation | Pharmaceutical Innovation
The future of pharmaceutical science is increasingly being shaped by technologies that bring together pharmaceutical engineering, advanced drug delivery, nanotechnology, materials science, data science and intelligent manufacturing.
This was at the heart of PharmSci 2026, the 17th PharmSci International Conference, held from 7–9 September 2026 at the Hilton Newcastle Gateshead, UK.
Organised by the Academy of Pharmaceutical Sciences (APS), this year’s conference explored the theme “Future Medicines: Powering Pharmaceutical Science Through Disciplinary Diversity”, bringing together academic and industry experts to examine the technologies and approaches shaping the development and delivery of next-generation medicines.
For Genvolt, PharmSci 2026 provided an important opportunity to showcase our growing expertise in electrohydrodynamic atomisation (EHDA), electrospinning, electrospraying and high-voltage engineering, while engaging with pharmaceutical scientists, researchers and industry professionals about the future of controlled and intelligent processing.
Genvolt at PharmSci 2026
Genvolt was proud to participate in PharmSci 2026 as an exhibitor and contributor to the conference’s Exhibitors Showcase.
On Monday 7 September, Genvolt delivered a presentation as part of the Exhibitors Showcase.
The presentation explored an important question for pharmaceutical researchers:
How much control do we really have over the way we manufacture the next generation of medicines?
The discussion focused on the role of electrohydrodynamic technology as a manufacturing tool, rather than simply as a laboratory technique.
For Genvolt, this distinction is important.
The objective is not simply to provide researchers with a high-voltage power supply or an electrospinning machine. It is to help them develop controlled, reproducible and application-specific experimental platforms that address the scientific problem they are trying to solve.
From High Voltage to Advanced Pharmaceutical Engineering
Genvolt’s foundation is high-voltage engineering.
With a history dating back to 1991, Genvolt has developed extensive expertise in the design and manufacture of high-voltage power supplies and tailor-made high-voltage solutions. The company’s stated mission is to develop and manufacture customised high-voltage solutions from 200 V to more than 300 kV, with certified systems conforming to ISO 9001:2015.
That engineering foundation has increasingly expanded into electrohydrodynamic atomisation (EHDA).
EHDA encompasses technologies such as electrospinning and electrospraying, where electrical forces are used to engineer formulation and generate fine fibres, particles and other structures.
For pharmaceutical research, these technologies offer exciting possibilities across areas including:
- Drug delivery
- Nanomedicine
- Nanofibre-based formulations
- Pharmaceutical formulation
- Tissue engineering
- Biomaterials
- Regenerative medicine
- Particle engineering
- Controlled-release systems
- Advanced coatings
Genvolt’s existing EHDA portfolio brings together high-voltage power supplies, precision syringe pumps, environmental chambers and modular electrospinning and electrospraying platforms to support laboratory research and development.
Why Process Control Matters in Electrospinning and Electrospraying
Producing a Taylor cone or generating a nanofibre is only one part of the challenge.
For pharmaceutical scientists, one of the more fundamental questions is:
Can the process be controlled and reproduced?
Electrospinning and electrospraying can be influenced by a range of parameters, including applied voltage, flow rate, formulation properties and environmental conditions.
Changes in temperature, humidity, airflow or material properties can influence the resulting fibres or particles.
This makes process control and reproducibility increasingly important as electrohydrodynamic technologies move from exploratory laboratory research towards more sophisticated pharmaceutical development.
Genvolt’s approach is therefore centred on bringing together the engineering elements required to provide researchers with greater control.
Our electrospinning and electrospraying solutions include precision high-voltage power supplies, syringe pumps and environmental control systems, with bespoke configurations available for more specialised research requirements.
Electrospinning and Electrospraying for Pharmaceutical Research
Electrospinning enables the production of fine nanofibrous structures, while electrospraying can generate micro- and nanoscale particles from liquid formulations.
These technologies can be particularly attractive for pharmaceutical and biomedical research because they provide researchers with routes to engineer material structures and drug-delivery platforms at very small scales.
Genvolt’s multi-syringe systems, for example, are designed for applications including multi-material electrospinning, electrospraying and advanced EHDA research, providing controlled delivery of multiple polymer or solution streams.
Genvolt also offers compact electrospinning chambers designed for controlled EHDA experimentation, with integrated high-voltage supply options and compatibility with syringe pumps and collectors.
The result is a modular approach that can be adapted as research requirements become more sophisticated.
From Standard Equipment to Bespoke EHDA Solutions
One of the key messages from Genvolt’s participation at PharmSci 2026 was that there is no single electrospinning system that is suitable for every research question.
A laboratory may require a simple single-needle electrospinning platform.
Another research group may require multiple needles or multiple material streams.
A pharmaceutical development project may require tighter environmental control.
Another application may require coaxial electrospinning, specialised collectors or a completely bespoke configuration.
This is where Genvolt’s high-voltage engineering heritage becomes particularly valuable.
Genvolt provides bespoke engineering solutions where standard products do not meet the required specifications. The company has a proven track record of developing high-voltage systems around specific customer requirements.
Sometimes the answer isn’t choosing a machine from a catalogue. Sometimes the answer is engineering the right machine for the science.
The Next Generation of EHDA: Intelligent and Adaptive Manufacturing
While improved equipment and process control are important, Genvolt believes the future of EHDA goes further.
The next step is intelligent EHDA.
Imagine an electrohydrodynamic manufacturing platform capable of sensing what is happening during the process, interpreting the resulting information and adapting its behaviour in real time.
This creates a pathway from:
Controlled manufacturing to Adaptive manufacturing.
Rather than relying entirely on predefined process parameters, future systems could use real-time information to help optimise deposition, improve reproducibility and support more complex manufacturing tasks.
This direction is particularly relevant to the wider themes discussed at PharmSci 2026, where the programme included sessions on digital technologies, AI, machine learning, advanced manufacturing and multidisciplinary approaches to future medicines.
Why Collaboration Matters
The theme of PharmSci 2026 — “Future Medicines: Powering Pharmaceutical Science Through Disciplinary Diversity” — strongly reflects Genvolt’s approach to innovation.
The most challenging problems in pharmaceutical manufacturing rarely belong to a single discipline.
Pharmaceutical scientists understand the formulation and therapeutic objectives.
Materials scientists understand how materials behave.
Engineers understand how to translate those requirements into reliable systems.
Automation specialists can introduce robotics, sensing and machine vision.
Data scientists and AI researchers can help transform process data into actionable information.
And industry provides the pathway towards reliability, reproducibility, scale-up and commercial deployment.
The real opportunity is at the intersection of these disciplines.
Building on Genvolt’s PharmSci Journey
Genvolt’s participation at PharmSci 2026 builds on its involvement in previous APS conferences.
At PharmSci 2025 in Cardiff, Genvolt showcased electrospinning and electrospraying technologies, including high-voltage power supplies, syringe pumps, environmental chambers and electrospinning starter kits. The focus included nanofibre and nanoparticle fabrication, drug delivery, tissue engineering and nanomedicine.
PharmSci 2026 represents the next stage of that conversation.
The focus is moving beyond simply asking:
“What equipment do you need?” towards: “What are you trying to achieve scientifically, and what technology do we need to engineer to make it possible?”
That shift is central to Genvolt’s expanding role in pharmaceutical engineering and EHDA technology.
Continuing the Conversation Beyond PharmSci 2026
PharmSci 2026 has provided an excellent opportunity for Genvolt to connect with researchers working at the forefront of pharmaceutical science and to discuss the challenges they face in electrospinning, electrospraying, drug delivery, nanofibre production and advanced pharmaceutical manufacturing.
But the conversations do not end when the conference closes.
Whether you are developing a new drug-delivery platform, investigating nanofibres, exploring particle engineering, working with biomaterials or looking for a bespoke electrohydrodynamic system, Genvolt can work with you to understand the technical requirements and explore an appropriate solution.
Our aim is straightforward: To give researchers greater control over their process.
And ultimately: From high voltage, to controlled processes, to better science.
Explore Genvolt’s Electrospinning and Electrospraying Solutions
Discover Genvolt’s range of electrospinning equipment, electrospraying systems, high-voltage power supplies, syringe pumps, environmental chambers and bespoke EHDA solutions for pharmaceutical, biomedical and advanced materials research.
Have a challenging EHDA application? Talk to the Genvolt team about your requirements.